1,3-dimethyl-4-pyridinone | 143798-69-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1,3-dimethyl-4-pyridinone
• 英文别名: 1,3-dimethyl-4-pyridone；1,3-Dimethyl-pyridon-(4)；1,3-Dimethylpyridin-4-one
• CAS: 143798-69-0
• 化学式: C₇H₉NO
• 分子量: 123.155
• InChiKey: HOCLMYVQINQGNJ-UHFFFAOYSA-N

物化性质

• 沸点：
  183.2±33.0 °C(Predicted)
• 密度：
  1.038±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-chloro-1,3-dimethylpyridine iodide 在 sodium hydroxide 作用下， 反应 1.0h， 以33%的产率得到1,3-dimethyl-4-pyridinone
  参考文献：
  名称：

  Hatton, Paul M.; Sternhell, Sever, Journal of Heterocyclic Chemistry, 1992, vol. 29, # 4, p. 935 - 946

  摘要：

  DOI：

文献信息

• Fluorinated derivatives of deferiprone
  申请人：Tam Tim Fat

  公开号：US20080242706A1

  公开（公告）日：2008-10-02

  The present invention relates to novel derivatives of deferiprone. In particular, the present invention relates to fluorinated derivatives of deferiprone or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, processes for the manufacture thereof and their use in the treatment of neurodegenerative diseases caused by the presence of free iron or iron accumulation in neural tissues and in diseases wherein excess iron must be removed or redistributed.

  本发明涉及延胜肽的新颖衍生物。具体地，本发明涉及延胜肽的氟化衍生物或其药用盐，包括相同的药物组成部分，制造这些药物组成部分的方法以及它们在治疗由游离铁或神经组织中铁积累引起的神经退行性疾病以及需要去除或重新分配过量铁的疾病中的用途。
• Solvent and substituent effects on the conversion of 4-methoxypyridines to N-methyl-4-pyridones
  作者：Xiao Yi、Jing Chen、Xiuling Xu、Yongmin Ma

  DOI：10.1080/00397911.2017.1290804

  日期：2017.5.3

  ABSTRACT In the reaction of 4-methoxypyridine derivatives with alkyl iodides in the presence or absence of solvent, not only the pyridinium ions but also the related 1-methylpyridones are produced. The presence of solvent favors the formation of the 1-methylpyridone. Electron withdrawing groups on the pyridine ring also favor this conversion. A possible mechanism is presented. GRAPHICAL ABSTRACT

  摘要 在有或无溶剂存在下，4-甲氧基吡啶衍生物与烷基碘反应，不仅生成吡啶鎓离子，而且生成相关的1-甲基吡啶酮。溶剂的存在有利于1-甲基吡啶酮的形成。吡啶环上的吸电子基团也有利于这种转化。提出了一种可能的机制。图形概要
• BENZENE DERIVATIVE OR SALT THEREOF
  申请人：Hirayama Fukushi

  公开号：US20090054352A1

  公开（公告）日：2009-02-26

  Problem: To provide compounds which have an anticoagulation effect based on their ability to inhibit the activated blood coagulation factor X and are useful as coagulation inhibitors or agents for prevention or treatment for diseases caused by thrombi or emboli. Means for Solution: Benzene derivatives or their salts having a characteristic chemical structure with a phenol ring and a benzene ring bonding to each other via an amide bond, in which the phenol ring further bonds to a benzene ring or a heteroaryl ring via an amide bond. They have an excellent effect of inhibiting the activated blood coagulation factor X, and especially have an excellent oral activity.

  问题：提供具有抗凝作用的化合物，其基于其抑制活化的血液凝血因子X的能力，并且可用作凝血抑制剂或用于预防或治疗由血栓或栓子引起的疾病的药物。 解决方法：苯衍生物或其盐具有特征化学结构，其中苯酚环和苯环通过酰胺键相互结合，其中苯酚环通过酰胺键进一步结合到苯环或杂环环上。它们具有出色的抑制活化的血液凝血因子X的效果，尤其是具有出色的口服活性。
• Fluorinated Derivatives of Deferiprone
  申请人：Tam Tim Fat

  公开号：US20120095061A1

  公开（公告）日：2012-04-19

  The present invention relates to novel derivatives of deferiprone. In particular, the present invention relates to fluorinated derivatives of deferiprone or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, processes for the manufacture thereof and their use in the treatment of neurodegenerative diseases caused by the presence of free iron or iron accumulation in neural tissues and in diseases wherein excess iron must be removed or redistributed.

  本发明涉及新型去铁酮衍生物。特别地，本发明涉及氟化去铁酮衍生物或其药学上可接受的盐、包含其的制药组合物、其制造过程以及在治疗由自由铁或神经组织中铁积累引起的神经退行性疾病和需要去除或重新分配过量铁的疾病中的应用。
• HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS
  申请人：Nishino Taito

  公开号：US20120128640A1

  公开（公告）日：2012-05-24

  An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided. An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells containing a compound represented by the formula (I) (wherein X, Y, Z, Ar 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R6 and R 7 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof, which can expand hematopoietic stem cells and/or hematopoietic progenitor cells.

  提供一种用于改善基因治疗中将基因转移至造血干细胞以治疗各种疾病的血液干细胞和/或造血祖细胞扩张剂。该扩张剂包含由式(I)表示的化合物（其中X、Y、Z、Ar1、R1、R2、R3、R4、R5、R6和R7如描述中所定义）、该化合物的互变异构体、前药或药学上可接受的盐或其溶剂，能够扩张血液干细胞和/或造血祖细胞。